125 related articles for article (PubMed ID: 23503517)
1. Targeting age-related changes in the biology of acute myeloid leukemia: is the patient seeing the progress?
Vey N
Interdiscip Top Gerontol; 2013; 38():73-84. PubMed ID: 23503517
[TBL] [Abstract][Full Text] [Related]
2. Pretreatment prognostic factors for overall survival in primary resistant acute myeloid leukemia.
Colovic N; Tomin D; Vidovic A; Suvajdzic N; Jankovic G; Palibrk V; Djunic I; Djurasinovic V; Virijevic M
Biomed Pharmacother; 2012 Dec; 66(8):578-82. PubMed ID: 23085253
[TBL] [Abstract][Full Text] [Related]
3. Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia.
Rao AV; Valk PJ; Metzeler KH; Acharya CR; Tuchman SA; Stevenson MM; Rizzieri DA; Delwel R; Buske C; Bohlander SK; Potti A; Löwenberg B
J Clin Oncol; 2009 Nov; 27(33):5580-6. PubMed ID: 19858393
[TBL] [Abstract][Full Text] [Related]
4. Elderly patients with acute myeloid leukaemia: characteristics in biology, patients and treatment. Recommendations of the Working Group Geriatric Oncology of the German Society for Haematology and Oncology (DGHO), the Austrian Society for Haematology and Oncology (OGHO) and the German Society for Geriatrics (DGG).
Wedding U; Bokemeyer C; Meran JG; ; ;
Onkologie; 2004 Feb; 27(1):72-82. PubMed ID: 15007253
[TBL] [Abstract][Full Text] [Related]
5. Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia.
Etienne A; Esterni B; Charbonnier A; Mozziconacci MJ; Arnoulet C; Coso D; Puig B; Gastaut JA; Maraninchi D; Vey N
Cancer; 2007 Apr; 109(7):1376-83. PubMed ID: 17326052
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98.
von Neuhoff C; Reinhardt D; Sander A; Zimmermann M; Bradtke J; Betts DR; Zemanova Z; Stary J; Bourquin JP; Haas OA; Dworzak MN; Creutzig U
J Clin Oncol; 2010 Jun; 28(16):2682-9. PubMed ID: 20439630
[TBL] [Abstract][Full Text] [Related]
7. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia.
Lugthart S; Gröschel S; Beverloo HB; Kayser S; Valk PJ; van Zelderen-Bhola SL; Jan Ossenkoppele G; Vellenga E; van den Berg-de Ruiter E; Schanz U; Verhoef G; Vandenberghe P; Ferrant A; Köhne CH; Pfreundschuh M; Horst HA; Koller E; von Lilienfeld-Toal M; Bentz M; Ganser A; Schlegelberger B; Jotterand M; Krauter J; Pabst T; Theobald M; Schlenk RF; Delwel R; Döhner K; Löwenberg B; Döhner H
J Clin Oncol; 2010 Aug; 28(24):3890-8. PubMed ID: 20660833
[TBL] [Abstract][Full Text] [Related]
8. The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups.
Schoch C; Kern W; Schnittger S; Büchner T; Hiddemann W; Haferlach T
Haematologica; 2004 Sep; 89(9):1082-90. PubMed ID: 15377469
[TBL] [Abstract][Full Text] [Related]
9. Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia.
Malfuson JV; Etienne A; Turlure P; de Revel T; Thomas X; Contentin N; Terré C; Rigaudeau S; Bordessoule D; Vey N; Gardin C; Dombret H;
Haematologica; 2008 Dec; 93(12):1806-13. PubMed ID: 18838471
[TBL] [Abstract][Full Text] [Related]
10. The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: studies of the Southwest Oncology Group Leukemia Research Program.
Willman CL
Semin Hematol; 1997 Oct; 34(4 Suppl 5):25-33. PubMed ID: 9408958
[TBL] [Abstract][Full Text] [Related]
11. [Therapy of acute myeloid leukemia (AML) for medically non-fit patients].
Fritsch S; Buske C; Wörmann B; Wedding U; Hiddemann W; Spiekermann K
Med Klin (Munich); 2007 Apr; 102(4):324-9. PubMed ID: 17426936
[TBL] [Abstract][Full Text] [Related]
12. Monosomal karyotype in acute myeloid leukemia predicts adverse treatment outcome and associates with high functional multidrug resistance activity.
Ahn HK; Jang JH; Kim K; Kim HJ; Kim SH; Jung CW; Kim DH
Am J Hematol; 2012 Jan; 87(1):37-41. PubMed ID: 22120708
[TBL] [Abstract][Full Text] [Related]
13. What is the optimal induction strategy for older patients?
Estey E
Best Pract Res Clin Haematol; 2011 Dec; 24(4):515-22. PubMed ID: 22127314
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience.
Plesa C; Chelghoum Y; Plesa A; Elhamri M; Tigaud I; Michallet M; Dumontet C; Thomas X
Cancer; 2008 Feb; 112(3):572-80. PubMed ID: 18085638
[TBL] [Abstract][Full Text] [Related]
15. Acute myeloid leukemia: 2013 update on risk-stratification and management.
Estey EH
Am J Hematol; 2013 Apr; 88(4):318-27. PubMed ID: 23526416
[TBL] [Abstract][Full Text] [Related]
16. [Prognostic significance of age and karyotype in the treatment of acute myeloid leukemia: results at our center].
Nahajevszky S; Kapás B; Adám E; Lovas N; Halm G; Gopcsa L; Tamáska J; Poros A
Orv Hetil; 2004 Jan; 145(4):167-72. PubMed ID: 14978882
[TBL] [Abstract][Full Text] [Related]
17. New agents for the treatment of acute myeloid leukemia.
Tallman MS
Best Pract Res Clin Haematol; 2006; 19(2):311-20. PubMed ID: 16516128
[TBL] [Abstract][Full Text] [Related]
18. Cytogenetic abnormalities and monosomal karyotypes in children and adolescents with acute myeloid leukemia: correlations with clinical characteristics and outcome.
Manola KN; Panitsas F; Polychronopoulou S; Daraki A; Karakosta M; Stavropoulou C; Avgerinou G; Hatzipantelis E; Pantelias G; Sambani C; Pagoni M
Cancer Genet; 2013 Mar; 206(3):63-72. PubMed ID: 23411131
[TBL] [Abstract][Full Text] [Related]
19. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.
Terwijn M; van Putten WL; Kelder A; van der Velden VH; Brooimans RA; Pabst T; Maertens J; Boeckx N; de Greef GE; Valk PJ; Preijers FW; Huijgens PC; Dräger AM; Schanz U; Jongen-Lavrecic M; Biemond BJ; Passweg JR; van Gelder M; Wijermans P; Graux C; Bargetzi M; Legdeur MC; Kuball J; de Weerdt O; Chalandon Y; Hess U; Verdonck LF; Gratama JW; Oussoren YJ; Scholten WJ; Slomp J; Snel AN; Vekemans MC; Löwenberg B; Ossenkoppele GJ; Schuurhuis GJ
J Clin Oncol; 2013 Nov; 31(31):3889-97. PubMed ID: 24062400
[TBL] [Abstract][Full Text] [Related]
20. Population-based age-specific incidences of cytogenetic subgroups of acute myeloid leukemia.
Bacher U; Kern W; Schnittger S; Hiddemann W; Haferlach T; Schoch C
Haematologica; 2005 Nov; 90(11):1502-10. PubMed ID: 16266897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
